← Leaderboards
Dennis Liang Fei
Stemsynergy Therapeutics, Inc.
$1,915,495
Attributed
$3,830,990
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,830,990 · 4
By mechanism
R44$3,030,992 · 2
R43$799,998 · 2
Top collaborators
- Matthew Knowe3 shared
- Darren Orton2 shared
Most similar at Stemsynergy Therapeutics, Inc.
Same institution · by research overlap
- Darren Orton$11,188,596
- Matthew Knowe$1,515,496
- William Russell Guerrant$472,800
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadToxic EffectPreclinical DevelopmentTumorigenesisBindingGrowthMalignant NeoplasmsGenetic TranscriptionPropertyDrug KineticsTissuesCell LineGenesTherapeutic AgentsSmall MoleculeSolubilityPharmaceutical PreparationsCancer CellParalogous GeneIn VitroInhibitorPhosphotransferasesFunctional GroupSmall Business Innovation Research Grant
Grant awards (5)
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents$1,060,173
R44 · FY2024 · CA · contact PI
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents$939,827
R44 · FY2023 · CA · contact PI
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer$1,030,992
R44 · FY2022 · CA · contact PI
Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents$399,999
R43 · FY2022 · CA · contact PI
Small Molecule Inhibitors of Notch Activation Complex Kinase (NACK) as Novel Cancer Therapeutic Agents$399,999
R43 · FY2020 · CA · contact PI